Intron/Exon structure of the ATR gene (ENSG00000175054).
There are two transcript isoforms of this gene, with 47 and 46 exons, respectively, spanning to an area of 129.59 kb. Exons are illustrated with vertical lines and boxes (A, B). Diagram in panel B represents only the exons' structure. Direction of transcription is shown by an arrow. The 6 th exon that is missing from ATR isoform 2 is indicated with an asterisk (A) or with blue colour box (B). Untranslated regions are in light pink, while coding regions are in deep pink. Start of translation (ATG) and stop codon (TGA) are also indicated.
Description
47 exons spanning to 129.59 kb.
Transcription
Two isoforms: isoform ATR-201 (ENST00000350721) (8248 bp) includes all 47 exons, while isoform ATR-202 (ENST00000383101) (8056 bp) does not include exon 6, deleting 192 nt (64 codons) from the mRNA. The translation start site is in exon 1.
Protein
Note ATR and ATM function in an overlapping, but nonredundant fashion, phosphorylating many of the same substrates. However, and in contrast to ATM, ATR's function is essential for cell viability. ATR-deficiency at the organismal level affects normal development, tissue homeostasis, and ageing. 
Description

Expression
Isoform 1 has ubiquitous expression with highest levels in testis. Isoform 2 has more specific expression (has found in pancreas, liver and placenta while is not detected in heart, testis and ovary).
Forced expression of ATR inhibits MyoD function, leading to loss of differentiation, as well as induces cell-cycle abnormalities (increased aneuploidy and elimination of IR-induced G1 arrest). Limited expression of ATR or overexpression of kinase dead forms of this protein increases cell sensitivity to a variety of DNA damage agents and replication inhibitors, such as ionizing radiation (IR), cis-platinum, hydroxy urea (HU), methylmethanesulfonate (MMS) and ultra violet (UV) irradiation, leading to significant losses in checkpoint control and cell viability. Loss of ATR results in DNA fragile site expression, a specific type of genomic instability.
Localisation
In the nucleus, where it is recruited to chromatin during S-phase and redistributes to distinct foci upon DNA damage, stalling of replication forks with replication inhibitors or hypoxia. ATR has also been found in PML (promyetocytic leukaemia protein) nuclear bodies of some types of cells. Kinase dead forms of ATR do not relocalize in response to IR and block nuclear translocation of RPA complex in a cell cycle-dependent manner.
Function
ATR essential maintains genome integrity by serving multiple roles in the cellular response to DNA damage and endogenous replication stress. It signals to regulate the firing of replication origins, the repair of damaged replication forks and to prevent the premature mitotic entry. Moreover, it critically functions directly at the sites of stalled forks by stabilizing components of the replisome to ensure completion of replication during recovery of stalled forks.
ATR-mediated activation of S-phase checkpoint ATR is activated during every S-phase and in response to many different types of damage, including double strand breaks (DSB), base adducts, crosslinks and replication stress. The structural requirement for ATR activation is a RPA-coated single-stranded DNA with a 5' double stranded primer junction. ATR recognition of the above DNA structure depends upon a protein cofactor, ATRIP (ATR-interacting protein), that regulates ATR localization and activation. The activity of ATR-ATRIP complex is directly stimulated by TOPBP1 (DNA topoisomerase II binding protein 1), which recruitment to DNA is facilitated by the 9-1-1 (Rad9-Rad1-Hus1) checkpoint clamp. Activated ATR signals to coordinate cell cycle transitions and repair through the phosphorylation of numerous of substrates including RAD17, p53, TopBP1 (via a feed-forward signalling loop that amplifies ATR-mediated signals), the mediator protein CEP164 and the downstream effector Chk1 (checkpoint kinase 1), which is the best characterized target of the ATR activity. Recombination proteins BRCA1 (breast cancer susceptibility gene 1), WRN (Werner's syndrome helicase), and BLM (Bloom's syndrome helicase) are ATR sunstrates as well. ATR also phosphorylates the Fanconi-anemia protein FANCD2 to regulate inter-strand crosslink repair as well as the nucleotide excision repair protein XPA to regulate its intracellular localization. Moreover, ATR interacts with the mismatch repair protein MSH2 (mutS homolog 2) to form a signalling module and regulate the phosphorylation of Chk1 and SMC1 (structure maintenance of chromosome 1). Upon replication stress ATR also phosphorylates the Ser-139 of H2AX/H2AFX, while is associated with the tyrosine kinase oncogene BCR-ABL after genotoxic stress. ATR-mediated stabilization of replication forks ATR has a crucial role in the maintenance of functional replication forks independent of its function in the activation of Rad53 (yeast homolog of checkpoint kinase 2). Among substrates of ATR on the replication forks are the proteins RPA1, RPA2, MCM2-7 (minichromosome maintenance 2-7) complex, MCM10, PCNA, replication factor C, Tim (Timeless)-Tipin complex, SMARCAL1 (HARP)-a SNF2 ATPdependent annealing helicase, and several polymerases, such as Pol alpha and Pol epsilon. Furthermore, a key target of ATR-ATRIP complex is Claspin, and is important both for S-phase checkpoint activation (via regulation of Chk1 phosphorylation) but also for replication forks stabilization (via interactions with Pol epsilon) even in normal cycling cells. ATR is found also associated with two components of the nucleosome remodelling and deacetylating complex, the chromodomain-helicase-DNA-binding protein 4 (CHD4) and the histone-deacetylase-2 (HDAC2). ATR also functions to stabilize fragile sites. In effect of all the above, the ATR's essential function for cell viability may be to respond to abundant sources of replication stress in normal cycling cells as well as after exposure to DNA damage agents. ATR implication in centrosomal function via: (a) Direct interaction with NBS1 (Nijmegen breakage syndrome 1) and BRCA1 pathway. 
Mutations
Somatic
Single nucleotide substitutions have been described in various types of carcinomas at total frequency 2%, mostly in heterozygous form. In particular, missense mutations have been found in the PI3/4 kinase catalytic domain and in FAT domain of breast and lung cancers respectively. Coding silent mutations have also been detected in carcinomas of stomach, breast, skin and central nervous system.
Implicated in
ATR haploinsufficiency in mismatch repair (MMR)-deficient cancers
Note Homozygous null mutations of ATR have not been reported in human cancers even in late-stage malignant cells and it is unlikely to exist given that mutations in both alleles of ATR gene lead to cell lethality. However, ATR gene has a potential increased susceptibility to somatic mutations in tumors with defective MMR, due to the presence of an A10 mononucleotide repeat in the exon 10 protein coding region. In particular, clinical reports have demonstrated that ATR is heterozygously mutated in certain types of tumors with mismatch repair deficiencies, including malignancies of the colon, the stomach and the endometrium. Although, it is not well understood how these mutations could contribute to the tumorigenic process, lines of evidence suggest that ATR serves as a haploinsufficient tumor suppressor in mismatch repairdeficient cells. Disruption of a single ATR allele gene in MLH1-deficient background significantly increases fragile site expression, chromosomal amplifications and rearrangements. The above chromosomal instability accompanied by hypersensitivity to genotoxic stress agents, such as hydroxyurea. Furthermore, mice with ATR+/-MLH1-/-genotype are more prone to early tumor development compared with ATR+/-or MLH1-/-counterparts. More recently has been reported that the combined ATR haploinsufficiency and MMRdeficiency that lead to chromosomal instability in colon cancer cells are also enhance the sensitivity of these cells to chemotherapeutic agent 5-fluorouracil, a standard treatment for colorectal cancers. The mechanism by which this occurs remains unclear. However, some findings suggest that MMR-deficient cells with partial reduced ATR activity are more prone to formation of DNA double strand breaks (DSBs). Additionally, partial inhibition of ATR has been reported to be significant for treatment of patients with high-microsatellite instability (MSI, a class of genomic instability clinically distinct from chromosome instability that is the result of mutations in MMR machinery) colorectal tumors increasing the diseasefree survival time. Prognosis Recent works have demonstrated that high-MSI endometrioid endometrial cancers harboring ATR mutations have worse survival compared to ATR wildtype high-MSI tumors, suggesting that the last ones might also have an improved prognosis compared to microsatellite stable (MSS) endometrial tumors. However, the prognostic significance of ATR mutations in MMR deficient cancers remains to be clarified. Cytogenetics ATR partial knockdown in colon cancer cell lines with defective MMR leads to the formation of chromosomal breaks and gaps, chromosome bridges and micronuclei, as well as to the formation of supernumerary centrosomes.
ATR-mutated Seckel syndrome (ATR-SS)
Note Seckel syndrome is a rare autosomal recessive disorder characterised by severe intrauterine growth retardation, profound microcephaly, dwarfism, mental retardation and isolated skeletal abnormalities. At least four distinct Seckel syndrome-causative genomic loci (Skl 1-4) have been identified but only two genetic defects are known in this disorder. Both of them impacting on ATR-dependent DNA damage signalling. The first identified defect was in ATR gene itself, concerning a hypomorphic single synonymous mutation (A>G 2101) that caused aberrant splicing of ATR. Pericentrin (PCNT), a core structural component of centrosomes, has also been identified as Seckel syndrome-causative gene. Cytogenetics Cells from ATR-SS patients exhibit increased sensitivity to DNA replication fork stalling (measured as nuclear fragmentation and micronucleus formation), impaired phosphorylation of ATR substrates, defective G2/M arrest and supernumerous mitotic centrosomes. Impaired ATR signalling is also characteristic of cells derived from other disorders with microcephaly and growth delay such as pericentrin-mutated Seckel syndrome (PCNT-SS), primary autosomal recessive microcephaly (MCPH) and Nijmegen breakage syndrome.
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